ADAPTIVE BIOTECHNOLOGIES COR's ticker is ADPT and the CUSIP is 00650F109. A total of 212 filers reported holding ADAPTIVE BIOTECHNOLOGIES COR in Q4 2021. The put-call ratio across all filers is 0.89 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,492,533 | -9.3% | 824,318 | +11.7% | 0.00% | -25.0% |
| Q2 2023 | $4,950,906 | -24.0% | 737,840 | +0.0% | 0.00% | -20.0% |
| Q1 2023 | $6,514,509 | +47.4% | 737,770 | +27.6% | 0.01% | +25.0% |
| Q4 2022 | $4,418,961 | +54.4% | 578,398 | +43.9% | 0.00% | +33.3% |
| Q3 2022 | $2,862,000 | +94.7% | 401,957 | +121.2% | 0.00% | +200.0% |
| Q2 2022 | $1,470,000 | -41.0% | 181,691 | +1.1% | 0.00% | -50.0% |
| Q1 2022 | $2,493,000 | -51.1% | 179,626 | -1.0% | 0.00% | -33.3% |
| Q4 2021 | $5,093,000 | +21.0% | 181,504 | +46.5% | 0.00% | 0.0% |
| Q3 2021 | $4,210,000 | -16.7% | 123,862 | +0.1% | 0.00% | 0.0% |
| Q2 2021 | $5,055,000 | -91.0% | 123,720 | -87.0% | 0.00% | -93.2% |
| Q4 2020 | $56,105,000 | +21.6% | 948,837 | -0.0% | 0.04% | +7.3% |
| Q3 2020 | $46,144,000 | +19.0% | 948,885 | +18.4% | 0.04% | +10.8% |
| Q2 2020 | $38,761,000 | +353.2% | 801,171 | +352.4% | 0.04% | +311.1% |
| Q2 2019 | $8,553,000 | – | 177,091 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Blue Water Life Science Advisors, LP | 2,377,665 | $12,958,274 | 12.23% |
| Eagle Health Investments LP | 1,214,860 | $6,620,987 | 1.46% |
| Matrix Capital Management Company, LP | 11,572,590 | $63,070,616 | 0.76% |
| Aristotle Atlantic Partners, LLC | 3,058,206 | $16,667,223 | 0.67% |
| VIKING GLOBAL INVESTORS LP | 29,993,708 | $163,465,709 | 0.66% |
| Pier Capital, LLC | 719,067 | $3,918,915 | 0.63% |
| DDD Partners, LLC | 783,697 | $3,385,571 | 0.49% |
| ARK Investment Management | 11,509,308 | $62,725,728 | 0.48% |
| Nikko Asset Management Americas, Inc. | 6,570,939 | $35,680,199 | 0.43% |
| Triatomic Management LP | 102,889 | $560,745 | 0.39% |